“As we anticipate four clinical readouts across the portfolio, 2024 is poised to be a transformative year for iTeos,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. “With the recent developments in the TIGIT field, we believe belrestotug is in an advantageous position and are excited for its future prospects. We look forward to sharing updates from our Phase 2 trials focused on 1L NSCLC and 1L HNSCC in 2024. Additionally, our strong comprehension of the adenosine pathway has enabled us to develop two innovative and optimized assets – inupadenant, an A2AR antagonist in a class of its own, and EOS-984, a potential first-in-class inhibitor targeting the novel mechanism of ENT1. With our strategic cash position and robust pipeline, we are focused on the execution of these clinical trials to deliver on our highly anticipated milestones this year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITOS:
- iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
- iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
- iTeos to Participate in Upcoming Investor Conferences
- iTeos Therapeutics announces 2024 strategic priorities, anticipated milestones